Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

224.47 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗

November 02, 2022

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.

Via Benzinga

What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

November 02, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗

October 27, 2022

Via Benzinga

Alnylam Pharmaceuticals: Q3 Earnings Insights ↗

October 27, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease ↗

October 07, 2022

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 13, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company ↗

October 13, 2022

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

October 11, 2022

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Via The Motley Fool

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 03, 2022

Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval ↗

October 03, 2022

Via Benzinga

Analyst Ratings for Alnylam Pharmaceuticals ↗

September 09, 2022

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

Via Benzinga

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 22, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program ↗

September 20, 2022

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers ↗

September 15, 2022

Via Benzinga

Why Alnylam Pharmaceuticals Shares Are Falling ↗

September 12, 2022

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

September 09, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗

September 08, 2022

Via Benzinga

Alnylam Shares Detailed Patisiran Data From Rare Disease Study ↗

September 08, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug ↗

August 29, 2022

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart? ↗

August 17, 2022

If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.